LifeX Ventures

LifeX Ventures positions as a longevity and human-performance focused investor, backing companies at the intersection of biology, consumer health, and software. With no published check size or stage discipline in the supplied data, treat this as a small, conviction-driven fund writing checks plausibly in the $250k to $1.5M range at pre-seed and seed, sometimes participating in larger Series A rounds led by a generalist. Healthcare exposure runs through the longevity stack, including diagnostics, supplements, biological aging interventions, and the digital health products that wrap around them. Physician founders working on aging biology, metabolic health, hormone medicine, or consumer-grade clinical tools are the cleanest fit. Founders building enterprise hospital software, traditional payer-contracted services, or therapeutics in trials are unlikely to land here without a longevity wrapper. Geographic posture appears global, with European and US deals both plausible. Entry is best through warm introduction from a longevity ecosystem operator, scientific advisor, or existing portfolio founder; cold pitches that lead with TAM rather than mechanism of action will not survive first read. Founders should bring a clear scientific narrative, a defensible IP or data moat, and an articulated path to either consumer pull or clinician adoption before requesting a meeting. Small-fund dynamics mean a lead investor will likely have to come from elsewhere; LifeX is best modeled as a high-conviction co-investor with category fluency rather than a round-defining anchor.